A study presented at the European Academy of Dermatology and Venereology Congress in Austria indicates that GLP-1 agonist weight-loss medications are linked to increased rates of nail detachment and scalp inflammation. Researchers observed that users of these injections experienced significantly higher frequencies of hair shedding and nail discoloration compared to a control group.
The 66 per cent nail disorder rate in GLP-1 users
According to the report presented at the European Academy of Dermatology and Venereology Congress, researchers analyzed a cohort of 575 patients using GLP-1 agonists, comparing them against 1,329 individuals with obesity or type 2 diabetes who had not used the drugs.. The findings revealed that 66 per cent of the medication users reported at least one nail disorder, a notable increase over the just-over-50 per cent reported by the non-user group.
The severity of these issues was particularly pronounced in the drug-user group, where nail detachment—a painful separation of the nail from the skin—occurred more than four times as often as in the control group. Additionally, the study found that 46 per cent of those receiving the injections experienced discoloration of their toenails or fingernails, compared to only 17 per cent of the comparison group.
How iron, zinc, and biotin deficiencies drive nail detachment
The research suggests that the dermatological decline may be a byproduct of the extreme speed of weight loss associated with drugs like Ozempic, Wegovy, and Mounjaro. As reported in the study, even when compared to a subgroup of patients who lost weight through traditional diet and exercise, the injection users still suffered more nail problems. This suggests that the metabolic stress of rapid weight loss triggers critical micronutrient deficiencies, specifically in iron,zinc, and biotin.
Because the human body prioritizes the function of vital organs during periods of intense metabolic stress, non-essential structures like nails and hair are often deprived of necessary nutrients. This biological triage can lead to nail dystrophy and other keratin-based tissue failures, making the rapid weight loss induced by GLP-1 agonists a primary suspect in these cosmetic complications.
Dr. Bruno Halioua's warning on inflammatory scalp redness
Beyond nail health, the study highlighted significant scalp distress, with approximately 50 per cent of GLP-1 users reporting increased hair shedding.. Hair thinning affected more than 40 per cent of the slimming participants, and scalp redness was observed three times more frequently in injection users than in the control group. These symptoms were rarely isolated, often appearing alongside scaling and itching.
Dr. Bruno Halioua, a co-author of the study, emphasized that these changes are not merely the result of muscle loss typical of rapid weight loss, but point toward an active inflammatory component of the scalp. While Dr. Halioua noted that these conditions can be managed with topical steroids and moisturizers, he warned that current medical practices often overlook the impact of GLP-1 agonists on scalp health.
The 1,252 UK MHRA reports on hair loss
The scale of these side effects is reflected in regulatory data from the UK Medicines and Healthcare products Regulatory Agency (MHRA).. Since the start of 2025, the MHRA has reecived 940 reports of hair loss linked to tirzepatide (the active ingredient in Mounjaro) and 312 reports linked to Ozempic and Wegovy.
Despite these numbers, several critical questions remain. The source does not clarify if these dermatological effects persist after a patient ceases the medication or if they are fully reversible once nutrient levels are restored. Furthermore, while the study compares drug users to diet-and-exercise groups, it remains unknown how these side effects compare to those experienced by patients undergoing bariatric surgery, which also causes rapid weight loss.
Comments 0